| Sample | Title | Value | Rank |
|---|
| GSM1256968 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 1 | 2829.62 | 99 |
| GSM1256969 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 2 | 2597.25 | 99 |
| GSM1256970 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 3 | 2432.57 | 98 |
| GSM1256971 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 4 | 2369.45 | 98 |
| GSM1256988 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 55 before YFV | 3385.6 | 99 |
| GSM1256991 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 55 seven days after YFV | 2557.57 | 99 |
| GSM1256989 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 56 before YFV | 3005.29 | 99 |
| GSM1256992 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 56 seven days after YFV | 2154.13 | 98 |
| GSM1256990 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 57 before YFV | 3380.32 | 99 |
| GSM1256993 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 57 seven days after YFV | 2820.72 | 99 |